BCOP Updates 2024: Spilling the “T“: Sharing Advancements of Bispecific T-cell Engaging Therapies in Hematologic Malignancies
This session aims to address updates in the development of bispecific antibody (BsAb) therapies for hematologic malignancies. Granted accelerated approval in 2014, blinatumomab was the first BsAb therapy option for acute lymphoblastic lymphoma (ALL). In recent years additional therapies have received approval for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM) with even more investigational agents on the horizon for these indications as well as others such as acute myeloid leukemia (AML).
Given the mechanism of action, these agents often pose safety concerns similar in nature to chimeric antigen T-cell (CAR) therapy, but also may introduce unique side effects. The session contents will provide an overview of each FDA-approved BsAb including study population and safety concerns. Supportive care, administration logistics, and cost will also be addressed.
BCOP Updates 2024: Spilling the “T“: Sharing Advancements of Bispecific T-cell Engaging Therapies in Hematologic Malignancies
Author: Michael Williams, PharmD, BCOP
UAN#: 0465-0000-24-087-H01-P
This session aims to address updates in the development of bispecific antibody (BsAb) therapies for hematologic malignancies. Granted accelerated approval in 2014, blinatumomab was the first BsAb therapy option for acute lymphoblastic lymphoma (ALL). In recent years additional therapies have received approval for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM) with even more investigational agents on the horizon for these indications as well as others such as acute myeloid leukemia (AML).
Given the mechanism of action, these agents often pose safety concerns similar in nature to chimeric antigen T-cell (CAR) therapy, but also may introduce unique side effects. The session contents will provide an overview of each FDA-approved BsAb including study population and safety concerns. Supportive care, administration logistics, and cost will also be addressed.
Learning Objectives:
- Identify the mechanistic target and indication for each FDA-approved BsAb therapy among hematologic malignancies.
- Recall package insert recommendations to aid decision-making for the appropriate administration setting.
- Provide supportive care recommendations for the prevention and management of BsAb-related adverse events in multiple myeloma.
- Apply knowledge of CRS and ICANS to compare risks between BsAbs and CAR T-cell therapy.
Get it Now!
Knowledge Course for Pharmacist
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.